Empowered Patient Podcast

Dr. Romain Micol, CEO, and Dr. Tom VanCott, Chief Scientific Officer, at Combined Therapeutics, are excited about the opportunities to design mRNA vaccines that target specific tissue cells to restrict protein expression and have stronger potency in the fight against infectious disease and cancer. They have designed their vaccine platform to keep the vaccine antigen expression at the injection site, protecting the liver, kidney, and heart.  Romain explains, "So mRNA vaccines are highly effective both for infectious diseases and, more recently, to treat cancer. It's an ideal technology that is relatively easy to make and to manufacture. It could be very rapid and can get expression in vivo where protein would be folded properly. We can currently use the mRNA vaccine to deliver multiple materials to prevent infectious diseases and also cure cancer." "The main challenge we see at Combined Therapeutics, both for vaccines for infectious disease and for cancer treatment, is in their biodistribution and potency. Ou